<DOC>
	<DOCNO>NCT00277641</DOCNO>
	<brief_summary>This research study evaluate effectiveness , tolerability , safety lamotrigine therapy treatment binge eat disorder associate obesity . Lamotrigine approve Food Drug Administration treatment bipolar disorder , approve use treatment binge eat disorder obesity .</brief_summary>
	<brief_title>Lamotrigine Treatment Binge Eating Disorder Associated With Obesity</brief_title>
	<detailed_description>This 17-week , parallel group , placebo-controlled , randomize , double-blind , flexible-dose , single-center study . It begin 1 2 week screen period washout medication evaluation protocol-specified criterion . The screening period consist least two visit , include initial screen visit baseline ( week 1 ) visit . The treatment period follow screen period last 16 week . Once subject enters treatment phase ( randomization ) dosage study medication 25 mg/qHS ( one placebo tablet night ) 14 day . On day 14 ( visit 2 begin week 3 ) , dosage increase , tolerate , 25 mg b.i.d . On day 28 ( visit 4 begin week 5 ) , dosage increase , tolerate , 50 mg b.i.d . On day 35 ( visit 5 begin week 6 ) , dosage increase , tolerate , 100 mg b.i.d . The dosage may decrease time side effect . If patient prefers , may take daily dose medication morning evening . If response inadequate response ( &lt; 50 % reduction binge eat episode compare baseline ) evident week 6 ( visit 6 ) , study medication may increase 150 mg b.i.d . If response inadequate response evident week 8 ( visit 7 ) , study medication may increase 200 mg b.i.d . During week 12 16 ( maintenance period ) dosage change unless medical reason ( e.g. , adverse effect ) require change . The minimum dosage allow 50 mg/day maximum dosage allow 400 mg/day . The 16-week treatment period follow medication discontinuation evaluation 1 week medication discontinuation ( week 17 ) . Efficacy safety evaluation do visit start baseline visit week 17 ( baseline , week 1 , 2 , 3 , 4 , 5 , 6 , 8 , 10 , 12 , 14 , 16 ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Binge-Eating Disorder</mesh_term>
	<mesh_term>Feeding Eating Disorders</mesh_term>
	<mesh_term>Bulimia</mesh_term>
	<mesh_term>Lamotrigine</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>Patients meet DSMIVTR criterion BED least last 6 month , determine Structured Clinical Interview DSMIVTR ( SCID ) ( 61 ) support Eating Disorder Examination ( EDE ) ( 62 ) . These criterion follow : Recurrent episodes binge eat . An episode binge eat characterize following : eating , discrete period time ( e.g. , within two hour period ) , amount food definitely large people would eat similar period time similar circumstance sense lack control eat episode ( e.g. , feel one stop eat control much one eating ) The binge eat episode associate least three follow : eat much rapidly normal eat uncomfortably full eat large amount food feeling physically hungry eat alone embarrass much one eat feeling disgust oneself , depress , feel guilty overeating Marked distress regard binge eating . The binge eating occur , average , least two day week six month . Does occur exclusively course bulimia nervosa anorexia nervosa . Obesity , define body mass index &gt; 30 kg/m2 . Men woman , age 18 65 . Have current body mass index &lt; 30 kg/m2 . Women pregnant lactate woman childbearing potential take adequate contraceptive measure . ( All woman childbearing potential negative pregnancy test enter study . ) Subjects display clinically significant suicidality homicidality . Subjects display current clinically unstable depressive bipolar disorder , define Montgomery Asberg Depression Rating Scale ( MADRS ) ( 63 ) &gt; 24 Young Mania Rating Scale ( YMRS ) ( 64 ) &gt; 8 . A current recent ( within 6 month start study medication ) DSMIVTR diagnosis substance abuse dependence . A lifetime history DSMIVTR psychotic disorder dementia . History personality disorder ( e.g. , schizotypal , borderline , antisocial ) might interfere assessment compliance study procedure . Clinically unstable medical disease , include cardiovascular , hepatic , renal , gastrointestinal , pulmonary , metabolic , endocrine systemic disease could interfere diagnosis , assessment , treatment binge eat disorder . Patients biochemically euthyroid prior enter study . History seizure , include febrile seizure childhood . Subjects require treatment drug might interact adversely obscure action study medication ( e.g. , stimulant , sympathomimetics , antidepressant , carbonic anhydrase inhibitor , antiobesity drug ) . Subjects received psychoactive medication ( zaleplon [ Sonata ] zolpidem [ Ambien ] need restlessness/insomnia ) within one week prior randomization . Subjects begin and/or receive formal psychotherapy ( cognitive behavioral therapy , interpersonal therapy , dietary behavioral therapy ) BED weight loss within past 3 month . Subjects previously enrol study previously treat lamotrigine . Subjects received experimental drug use experimental device within 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Binge Eating Disorder Associated Obesity</keyword>
</DOC>